

Global Parkinsons Disease Drugs Market Outlook 2022

<https://marketpublishers.com/r/G9026A9057EEN.html>

Date: January 2018

Pages: 100

Price: US\$ 2,000.00 (Single User License)

ID: G9026A9057EEN

Abstracts

Parkinson's disease is a long term neurodegenerative disorder which affects the dopamine producing neurons in specific areas of the brain known as substantia nigra. This disease belongs to a group of conditions called motor system disorders. The symptoms for Parkinson's disease develop slowly over the years. The four primary symptoms of Parkinson's disease are tremors, rigidity, slowness of movement and postural instability. Although, there is no cure for Parkinson's disease, several medications are used to suppress the symptoms of the disease.

According to RNCOS report "Global Parkinson's Disease Drugs Market Outlook 2022", the global Parkinson's disease drugs market is anticipated to witness a moderate growth during 2016-2022. The report provides information about the current and future market scenario of the global Parkinson's disease drugs market. The report also highlights the major drivers, such as increasing awareness about Parkinson's disease and its treatment options, research grants and funds, for the global Parkinson's disease drugs market. Furthermore, the recent approval of novel Parkinson's disease drugs, which includes generic versions and first ever Parkinson related dyskinesia drug, is also expected to drive the global market of drugs for this disease.

Moreover, few hindrances, such as high cost of treatment and patent expiry of blockbuster drugs, which are slowing down the growth of the global Parkinson's disease drugs market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global Parkinson's disease drugs market.

The global Parkinson's disease drugs market has been segmented on the basis of type of therapy into levodopa therapy, dopamine therapy, MAO-B inhibitor therapy, COMT

inhibitor therapy, and other types of therapies. Among all the types, levodopa therapy is the first and most potent treatment for the Parkinson's disease. The benefits of the medication are witnessed soon after administration.

Numerous pharmaceutical and biotech companies are also developing novel treatment options, such as stem cell therapy, for the treatment of Parkinson's disease. Stem cell therapy is an evolving field which makes use of stem cells to treat or prevent a disease or condition, such as Parkinson's disease. Even a minimal success from this procedure can mean significant improvement in quality of life for patients. SanBio Inc and International Stem Cell Corp are some of the companies carrying out clinical trials for stem cell therapies for the treatment of Parkinson's disease. Hence, stem cell therapy presents great opportunities for the growth of global Parkinson's disease drugs market in the coming years.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global Parkinson's disease drugs market. Moreover, the report also highlights various mergers and acquisitions taking place in the global Parkinson's disease drugs industry. The drugs pipeline of Parkinson's disease has also been mentioned in the report.

The prominent players in global Parkinson's disease drugs market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global Parkinson's disease drugs market.

Contents

1. ANALYST VIEW

2. RESEARCH METHODOLOG

3. PARKINSON'S DISEASE: AN OVERVIEW

4. MARKET DYNAMICS

4.1 Drivers

- 4.1.1 Increasing Funding Support & Research Grants
- 4.1.2 Increasing Awareness
- 4.1.3 Rising Healthcare Expenditure
- 4.1.4 Increasing Life Expectancy

4.2 Challenges

- 4.2.1 Patent Expiry of Blockbuster Drugs
- 4.2.2 High Cost of Treatment
- 4.2.3 Side-Effects of Parkinson's Disease Drugs

4.3 Opportunities

- 4.3.1 Collaborations with Academic Institutions for Developing Innovative Solutions
- 4.3.2 Reduction in "Off" Time to Improve Patient and Economic Outcomes
- 4.3.3 Growing Geriatric Population

5. GLOBAL PARKINSON'S DISEASE DRUGS MARKET OUTLOOK 2022

6. MAJOR PRODUCTS IN PARKINSON'S DISEASE MARKET

- 6.1 Duodopa/Duopa
- 6.2 Azilect
- 6.3 Mirapex/Mirapex ER
- 6.4 Requip
- 6.5 Neupro
- 6.6 Rytary/Numient
- 6.7 Xadago
- 6.8 Nuplazid

7. MARKET SEGMENTATION BY TYPE OF THERAPY

- 7.1 Levodopa Therapy
- 7.2 Dopamine Agonist Therapy
- 7.3 MAO-B Inhibitor Therapy
- 7.4 COMT Inhibitor Therapy
- 7.5 Other Therapy

8. MARKET SEGMENTATION BY GEOGRAPHY

- 8.1 North America
- 8.2 Europe
- 8.3 Asia-Pacific

9. TRENDS & DEVELOPMENTS

- 9.1 Stem Cell Therapies - Revolutionizing Parkinson Treatment
- 9.2 Incessant Launch of Novel Products

10. MERGERS & ACQUISITIONS

11. DRUGS PIPELINE OF PARKINSON'S DISEASE

12. COMPANY PROFILES

- 12.1 Abbvie Inc.
- 12.2 Newron Pharmaceuticals SpA
- 12.3 Acadia Pharmaceuticals Inc.
- 12.4 Boehringer Ingelheim International GmbH
- 12.5 Teva Pharmaceutical Industries Limited
- 12.6 GlaxoSmithKline plc
- 12.7 UCB S.A.
- 12.8 Novartis AG
- 12.9 Impax Laboratories, Inc.
- 12.10 Valeant Pharmaceuticals International, Inc.
- 12.11 Merck & Co., Inc.
- 12.12 Mylan N.V.
- 12.13 F. Hoffmann-La Roche Ltd.
- 12.14 US WorldMeds, LLC

List Of Figures

LIST OF FIGURES:

- Figure 4-1: Global - Population 60 Years or Above (Billion), 2015, 2030 & 2050
- Figure 5-1: Global - Parkinson's Disease Drugs Market (Billion US\$), 2016 & 2022
- Figure 6-1: Global - Sales of Duodopa/Duopa (Billion US\$), 2015 & 2016
- Figure 6-2: Global - Sales of Azilect (Billion US\$), 2015 & 2016
- Figure 6-3: Global - Sales of Mirapex/Mirapex ER (Billion US\$), 2015 & 2016
- Figure 6-4: Global - Sales of Requip (Billion US\$), 2015 & 2016
- Figure 6-5: Global - Sales of Neupro (Billion US\$), 2015 & 2016
- Figure 6-6: Global - Sales of Rytary/Numient (Billion US\$), 2015 & 2016
- Figure 7-1: Global - Parkinson's Disease Drugs Market by Type of Therapy (%), 2016
- Figure 7-2: Global - Levodopa Therapy Market for Parkinson's Disease (Billion US\$), 2016 & 2022
- Figure 7-3: Global - Dopamine Agonist Therapy Market for Parkinson's Disease (Billion US\$), 2016 & 2022
- Figure 7-4: Global - MAO-B Inhibitor Therapy Market for Parkinson's Disease (Billion US\$), 2016 & 2022
- Figure 7-5: Global - COMT Inhibitor Therapy Market for Parkinson's Disease (Billion US\$), 2016 & 2022
- Figure 7-6: Global - Other Therapy Market for Parkinson's Disease (Billion US\$), 2016 & 2022
- Figure 8-1: Global - Parkinson's Disease Drugs Market by Geography (%), 2016
- Figure 8-2: North America - Parkinson's Disease Drugs Market (Billion US\$), 2016 & 2022
- Figure 8-3: North America - Population 60 Years or Above (Million), 2015, 2030 & 2050
- Figure 8-4: Europe - Parkinson's Disease Drugs Market (Billion US\$), 2016 & 2022
- Figure 8-5: Asia-Pacific - Parkinson's Disease Drugs Market (Billion US\$), 2016 & 2022
- Figure 12-1: Abbvie Inc. - Breakup of Revenue by Geography (%), 2016
- Figure 12-2: Boehringer Ingelheim International GmbH - Breakup of Sales by Business Segment (%), 2016
- Figure 12-3: Boehringer Ingelheim International GmbH - Breakup of Sales by Geography (%), 2016
- Figure 12-4: Teva Pharmaceutical Industries Limited - Breakup of Revenue by Business Segment (%), 2016
- Figure 12-5: Teva Pharmaceutical Industries Limited - Breakup of Revenue by Geography (%), 2016
- Figure 12-6: GlaxoSmithKline plc - Breakup of Group Turnover by Business Segment

(%), 2016

Figure 12-7: GlaxoSmithKline plc - Breakup of Group Turnover by Geography (%), 2016

Figure 12-8: UCB S.A. - Breakup of Revenue by Geography (%), 2016

Figure 12-9: Novartis AG - Breakup of Sales by Business Segment (%), 2016

Figure 12-10: Novartis AG - Breakup of Pharmaceuticals Division Sales by Segment (%), 2016

Figure 12-11: Novartis AG - Breakup of Sales by Geography (%), 2016

Figure 12-12: Impax Laboratories, Inc. - Breakup of Revenue by Business Segment (%), 2016

Figure 12-13: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Business Segment (%), 2016

Figure 12-14: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Geography (%), 2016

Figure 12-15: Merck & Co., Inc. - Sales by Business Segments (%), 2016

Figure 12-16: Merck & Co., Inc. - Sales by Geography (%), 2016

Figure 12-17: Mylan N.V. - Breakup of Revenue by Geography (%), 2016

Figure 12-18: F. Hoffmann-La Roche Ltd. - Breakup of Sales by Business Segment (%), 2016

List Of Tables

LIST OF TABLES:

Table 10-1: Mergers, Acquisitions & Collaborations in Parkinson's Disease Drugs Market (2015-2017)

Table 11-1: Global - Drugs Pipeline of Parkinson's Disease

Table 12-1: Abbvie Inc. - Key Financials (Billion US\$), 2014-2016

Table 12-2: Abbvie Inc. - Marketed Parkinson's Disease Products

Table 12-3: Abbvie Inc. - Parkinson's Disease Products in Pipeline

Table 12-4: Newron Pharmaceuticals SpA - Key Financials (Million US\$), 2014-2016

Table 12-5: Newron Pharmaceuticals SpA - Marketed Parkinson's Disease Products

Table 12-6: Newron Pharmaceuticals SpA - Parkinson's Disease Products in Pipeline

Table 12-7: Acadia Pharmaceuticals Inc. - Key Financials (Million US\$), 2014-2016

Table 12-8: Acadia Pharmaceuticals Inc. - Marketed Parkinson's Disease Products

Table 12-9: Boehringer Ingelheim International GmbH - Key Financials (Billion US\$), 2014-2016

Table 12-10: Boehringer Ingelheim International GmbH - Marketed Parkinson's Disease Products

Table 12-11: Teva Pharmaceutical Industries Limited - Key Financials (Billion US\$), 2014-2016

Table 12-12: Teva Pharmaceutical Industries Limited - Marketed Parkinson's Disease Products

Table 12-13: GlaxoSmithKline plc - Key Financials (Billion US\$), 2014-2016

Table 12-14: GlaxoSmithKline plc - Marketed Parkinson's Disease Products

Table 12-15: UCB S.A. - Key Financials (Billion US\$), 2014-2016

Table 12-16: UCB S.A. - Marketed Parkinson's Disease Products

Table 12-17: UCB S.A. - Parkinson's Disease Products in Pipeline

Table 12-18: Novartis AG - Key Financials (Billion US\$), 2014-2016

Table 12-19: Novartis AG - Marketed Parkinson's Disease Products

Table 12-20: Impax Laboratories, Inc. - Key Financials (Million US\$), 2014-2016

Table 12-21: Impax Laboratories, Inc. - Marketed Parkinson's Disease Products

Table 12-22: Impax Laboratories, Inc. - Parkinson's Disease Products in Pipeline

Table 12-23: Valeant Pharmaceuticals International, Inc. - Key Financials (Billion US\$), 2014-2016

Table 12-24: Valeant Pharmaceuticals International, Inc. - Marketed Parkinson's Disease Products

Table 12-25: Merck & Co., Inc. - Key Financials (Million US\$), 2014-2016

Table 12-26: Merck & Co., Inc. - Marketed Parkinson's Disease Products

Table 12-27: Mylan N.V. - Key Financials (Billion US\$), 2014-2016

Table 12-28: Mylan N.V. - Marketed Parkinson's Disease Products

Table 12-29: F. Hoffmann-La Roche Ltd. - Key Financials (Billion US\$), 2014-2016

Table 12-30: F. Hoffmann-La Roche Ltd. - Marketed Parkinson's Disease Products

Table 12-31: F. Hoffmann-La Roche Ltd. - Parkinson's Disease Products in Pipeline

Table 12-32: US WorldMeds, LLC - Marketed Parkinson's Disease Products

Table 12-33: US WorldMeds, LLC - Parkinson's Disease Products in Pipeline

I would like to order

Product name: Global Parkinsons Disease Drugs Market Outlook 2022

Product link: <https://marketpublishers.com/r/G9026A9057EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9026A9057EEN.html>